The board of Q-linea AB (publ) ("Q-linea" or the "Company") has decided to change the date for the publication of the Interim Report for the first quarter.

The reason for the postponement of the report is that Q-linea is in a negotiation process for a new financing structure to ensure necessary capital mainly to finance the ongoing market launch of ASTar in the US. The Board of Directors has found it most appropriate to further postpone the publication of the interim report for the first quarter 2024 to 31 May 2024 at 7.30 a.m.

For more information, please contact:

Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com
+1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20

About Q-linea

Q-linea’s rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.
Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.
ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

Attachments

Changed date for Interim Report

© Modular Finance, source Nordic Press Releases